Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15 2021 - 8:05AM
Business Wire
- Live webcast presentation on Wednesday,
September 22nd at 10:45 AM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced
that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow,
PhD, Chief Scientific Officer and Senior Vice President for Medical
Affairs of Cyclo Therapeutics, will present at the virtual
Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on
September 22, 2021 at 10:45 AM ET.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference.
The live webcast of the presentation will be accessible on the
Events page in the Investors section of the Company’s website
(www.cyclotherapeutics.com). The webcast replay will be archived
for 90 days following the live presentation.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210915005076/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2023 to Apr 2024
